Abstract
Gefitinib, a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is recommended for treatment of non-small cell lung cancer (NSCLC) patients w......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
